Frontiers in Immunology (Nov 2020)

Therapeutic Targeting of Retinal Immune Microenvironment With CSF-1 Receptor Antibody Promotes Visual Function Recovery After Ischemic Optic Neuropathy

  • Yizhen Tang,
  • Yizhen Tang,
  • Yizhen Tang,
  • Yizhen Tang,
  • Zebin Xiao,
  • Li Pan,
  • Li Pan,
  • Dongli Zhuang,
  • Dongli Zhuang,
  • Dongli Zhuang,
  • Kin-Sang Cho,
  • Kyle Robert,
  • Xiaoxiao Chen,
  • Xiaoxiao Chen,
  • Xiaoxiao Chen,
  • Lian Shu,
  • Lian Shu,
  • Lian Shu,
  • Guangxian Tang,
  • Jihong Wu,
  • Jihong Wu,
  • Jihong Wu,
  • Xinghuai Sun,
  • Xinghuai Sun,
  • Xinghuai Sun,
  • Dong F. Chen

DOI
https://doi.org/10.3389/fimmu.2020.585918
Journal volume & issue
Vol. 11

Abstract

Read online

Retinal ischemia/reperfusion injury (RI) is a common cause of irreversible visual impairment and blindness in elderly and critical unmet medical need. While no effective treatment is available for RI, microglial activation and local immune responses in the retina are thought to play important roles in the pathophysiology of neurodegeneration. While survival and activation of microglia depend critically on colony-stimulating factor receptor (CSF-1R) signaling, it remains unclear if targeting the retinal immune microenvironments by CSF-1RAb after RI is sufficient to rescue vision and present a potentially effective therapy. Here we used rodent models of RI and showed that retinal ischemia induced by acute elevation of intraocular pressure triggered an early activation of microglia and macrophages in the retina within 12 h. This was followed by lymphocyte infiltration and increased production of pro-inflammatory cytokines. Intravitreal injection of CSF-1R neutralizing antibody (CSF-1RAb) after RI significantly blocked microglial activation and the subsequent T cell recruitment. This also led to improved retinal ganglion cell survival and function measured by cell quantification and electroretinogram positive scotopic threshold responses, as well as increased visual acuity and contrast sensitivity as assessed by optomotor reflex-based assays, when compared to the isotype-treated control group. Moreover, the administration of CSF-1RAb efficiently attenuated inflammatory responses and activation of human microglia in culture, suggesting a therapeutic target with human relevance. These results, together with the existing clinical safety profiles, support that CSF-1RAb may present a promising therapeutic avenue for RI, a currently untreatable condition, by targeting microglia and the immune microenvironment in the retina to facilitate neural survival and visual function recovery.

Keywords